top of page
Resources
Health
Technology
Energy
Latest
Explainers
More
Use tab to navigate through the menu items.
Subscribe
Opthea’s Wet AMD Drug Fails Phase 3 Endpoints; in Discussion with Creditors
Opthea Ltd. (ASX/NASDAQ: OPT) announced that its COAST Phase 3 trial for wet age-related macular degeneration (wet AMD) failed to meet...
Health
Mar 26
bottom of page